MX2019015318A - Antagonistas del receptor del factor liberador de corticotropina. - Google Patents
Antagonistas del receptor del factor liberador de corticotropina.Info
- Publication number
- MX2019015318A MX2019015318A MX2019015318A MX2019015318A MX2019015318A MX 2019015318 A MX2019015318 A MX 2019015318A MX 2019015318 A MX2019015318 A MX 2019015318A MX 2019015318 A MX2019015318 A MX 2019015318A MX 2019015318 A MX2019015318 A MX 2019015318A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor antagonists
- factor receptor
- releasing factor
- corticotropin releasing
- dimethylpyrazolo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762545393P | 2017-08-14 | 2017-08-14 | |
| PCT/US2018/046707 WO2019036472A1 (en) | 2017-08-14 | 2018-08-14 | CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019015318A true MX2019015318A (es) | 2020-07-20 |
Family
ID=65362465
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019015318A MX2019015318A (es) | 2017-08-14 | 2018-08-14 | Antagonistas del receptor del factor liberador de corticotropina. |
| MX2022015858A MX2022015858A (es) | 2017-08-14 | 2019-12-16 | Antagonistas del receptor del factor liberador de corticotropina. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022015858A MX2022015858A (es) | 2017-08-14 | 2019-12-16 | Antagonistas del receptor del factor liberador de corticotropina. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210137935A1 (enExample) |
| EP (1) | EP3630763A4 (enExample) |
| JP (2) | JP7285222B2 (enExample) |
| KR (1) | KR102644781B1 (enExample) |
| CN (1) | CN110997667A (enExample) |
| AR (1) | AR112471A1 (enExample) |
| AU (3) | AU2018318990B2 (enExample) |
| BR (1) | BR112020002966A2 (enExample) |
| CA (1) | CA3064445A1 (enExample) |
| EA (1) | EA202090321A1 (enExample) |
| MX (2) | MX2019015318A (enExample) |
| TW (2) | TWI803504B (enExample) |
| WO (1) | WO2019036472A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3096756T (pt) | 2014-01-21 | 2024-08-26 | Neurocrine Biosciences Inc | Antagonistas do recetor crf1 para o tratamento da hiperplasia adrenal congénita |
| BR112020002967A2 (pt) | 2017-08-14 | 2020-08-11 | Spruce Biosciences, Inc. | antagonistas de receptor de fator de liberação de corticotropina |
| AU2018318990B2 (en) * | 2017-08-14 | 2023-01-05 | Spruce Biosciences, Inc. | Corticotropin releasing factor receptor antagonists |
| WO2019210266A1 (en) * | 2018-04-27 | 2019-10-31 | Spruce Biosciences, Inc. | Methods for treating testicular and ovarian adrenal rest tumors |
| MA54395A (fr) | 2018-12-07 | 2022-03-16 | Neurocrine Biosciences Inc | Antagoniste du récepteur crf1, formulations pharmaceutiques et formes solides correspondantes pour le traitement de l'hyperplasie surrénalienne congénitale |
| EP3986416A4 (en) * | 2019-07-19 | 2023-06-28 | Spruce Biosciences, Inc. | Methods of treating congenital adrenal hyperplasia |
| US12383536B2 (en) | 2019-09-27 | 2025-08-12 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods of use |
| WO2022036123A1 (en) | 2020-08-12 | 2022-02-17 | Spruce Biosciences, Inc. | Methods and compositions for treating polycystic ovary syndrome |
| US20240024330A1 (en) * | 2020-08-26 | 2024-01-25 | Neurocrine Biosciences, Inc. | Crf receptor antagonists and methods of use |
| US11708372B2 (en) | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
| WO2025188842A1 (en) * | 2024-03-08 | 2025-09-12 | Spruce Biosciences, Inc. | Amorphous solid dispersion of tildacerfont formulations |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL123835A0 (en) | 1996-02-07 | 1998-10-30 | Janssen Pharmaceutica Nv | Pyrazolopyrimidines as CRF receptor antagonists |
| CN1137123C (zh) | 1998-01-28 | 2004-02-04 | 杜邦药品公司 | 吡咯并三嗪和嘧啶化合物 |
| IL137019A (en) * | 1998-01-28 | 2010-11-30 | Du Pont Pharm Co | 2,7 - dimethyl - 4 - (substituted amino) - 8 - arylpyrazolo [1,5-a] triazine derivatives and pharmaceutical compositions containing them |
| KR100664479B1 (ko) * | 1999-12-08 | 2007-01-04 | 파마시아 코포레이션 | 발데콕시브 조성물 |
| EP1722826A2 (en) * | 2004-02-13 | 2006-11-22 | SB Pharmco Puerto Rico Inc. | Crf receptor antagonists, their preparations, their pharmaceutical composition and their uses |
| US7612067B2 (en) | 2005-03-21 | 2009-11-03 | Eli Lilly And Company | Imidazopyridazine compounds |
| BRPI0717070A2 (pt) * | 2006-09-20 | 2013-09-24 | Lilly Co Eli | compostos de tiofeno pirazolopirimidina |
| HRP20100516T1 (hr) * | 2006-09-20 | 2010-10-31 | Eli Lilly And Company | Tiazolpirazolopirimidini kao antagonisti receptora crf1 |
| CA2739422C (en) * | 2008-10-02 | 2013-03-12 | Eli Lilly And Company | Thiazolyl-pyrazolopyrimidine compounds as synthetic intermediates and related synthetic processes |
| AU2018318990B2 (en) * | 2017-08-14 | 2023-01-05 | Spruce Biosciences, Inc. | Corticotropin releasing factor receptor antagonists |
-
2018
- 2018-08-14 AU AU2018318990A patent/AU2018318990B2/en active Active
- 2018-08-14 EP EP18846043.0A patent/EP3630763A4/en active Pending
- 2018-08-14 CA CA3064445A patent/CA3064445A1/en active Pending
- 2018-08-14 WO PCT/US2018/046707 patent/WO2019036472A1/en not_active Ceased
- 2018-08-14 US US16/639,540 patent/US20210137935A1/en not_active Abandoned
- 2018-08-14 BR BR112020002966-1A patent/BR112020002966A2/pt not_active Application Discontinuation
- 2018-08-14 KR KR1020207005534A patent/KR102644781B1/ko active Active
- 2018-08-14 TW TW107128345A patent/TWI803504B/zh active
- 2018-08-14 JP JP2019572820A patent/JP7285222B2/ja active Active
- 2018-08-14 EA EA202090321A patent/EA202090321A1/ru unknown
- 2018-08-14 CN CN201880038596.0A patent/CN110997667A/zh active Pending
- 2018-08-14 TW TW112117030A patent/TW202400179A/zh unknown
- 2018-08-14 MX MX2019015318A patent/MX2019015318A/es unknown
- 2018-08-14 AR ARP180102314 patent/AR112471A1/es unknown
-
2019
- 2019-12-16 MX MX2022015858A patent/MX2022015858A/es unknown
-
2023
- 2023-03-20 AU AU2023201703A patent/AU2023201703B2/en active Active
- 2023-05-22 JP JP2023084119A patent/JP7720354B2/ja active Active
-
2024
- 2024-12-16 AU AU2024278470A patent/AU2024278470A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3064445A1 (en) | 2019-02-21 |
| AU2024278470A1 (en) | 2025-01-09 |
| WO2019036472A1 (en) | 2019-02-21 |
| BR112020002966A2 (pt) | 2020-08-11 |
| MX2022015858A (es) | 2023-01-24 |
| AU2018318990B2 (en) | 2023-01-05 |
| JP7720354B2 (ja) | 2025-08-07 |
| CN110997667A (zh) | 2020-04-10 |
| TWI803504B (zh) | 2023-06-01 |
| AU2023201703B2 (en) | 2024-09-19 |
| EP3630763A4 (en) | 2021-03-10 |
| TW202400179A (zh) | 2024-01-01 |
| KR20200038951A (ko) | 2020-04-14 |
| KR102644781B1 (ko) | 2024-03-06 |
| AU2018318990A1 (en) | 2019-11-21 |
| EA202090321A1 (ru) | 2020-09-24 |
| US20210137935A1 (en) | 2021-05-13 |
| JP7285222B2 (ja) | 2023-06-01 |
| JP2023116489A (ja) | 2023-08-22 |
| AU2023201703A1 (en) | 2023-04-13 |
| AR112471A1 (es) | 2019-10-30 |
| TW201925197A (zh) | 2019-07-01 |
| JP2020530832A (ja) | 2020-10-29 |
| EP3630763A1 (en) | 2020-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019015318A (es) | Antagonistas del receptor del factor liberador de corticotropina. | |
| MX2019015320A (es) | Antagonistas del receptor del factor liberador de corticotropina. | |
| MX2025003987A (es) | Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos | |
| ES3052613T3 (en) | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia | |
| CL2019000942A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret. | |
| ZA202204284B (en) | Inhibitors of raf kinases | |
| WO2019123294A3 (en) | Pyrazolo piperidine and pyrazolo pyrimidine derivatives for the treatment of neuropsychiatric systemic lupus erythematosus | |
| DOP2017000199A (es) | Receptores de antígeno quiméricos ant- dll3 y métodos de uso | |
| CL2016002836A1 (es) | Compuestos derivados de pirido pirimidin con actividad moduladora del empalme genico de smn2; composicion farmaceutica y uso en el tratamiento de la atrofia muscular espinal (ame). | |
| NZ736055A (en) | Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators | |
| SI3230298T1 (sl) | Spojine 3-substituiranega 5-amino-6H-tiazolo(4,5-d)pirimidin-2,7-diona za zdravljenje ali preprečevanje okužbe z virusom | |
| UY37559A (es) | Pirazolo[3,4-b]piridina y pirrolo[2,3-b]piridina como inhibidores de la tirosina quinasa de bruton | |
| PH12017500161B1 (en) | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | |
| WO2018067520A3 (en) | Therapeutic agents and methods: | |
| MX2017001454A (es) | Compuestos de 6,7-dihidropirazolo[1,5-a]pirazin-4(5h)-ona y su uso como moduladores alostericos negativos de receptores de glutamato metabotropico subtipo 2 (mglu2r2). | |
| MX2020012980A (es) | Composiciones y métodos para incrementar la exposición plasmática de tetrahidrobiopterina. | |
| WO2020089687A3 (en) | Fused heterocyclic benzodiazepine derivatives and uses thereof | |
| AU2016348418A8 (en) | Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same | |
| WO2018094106A3 (en) | ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES | |
| JO3601B1 (ar) | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 | |
| CL2016002482A1 (es) | Compuestos de azol sustituidos con amida como inhibidores de tnks1 y/o tnks2. | |
| SI3596080T1 (sl) | Farmakološko aktivni aliciklični-substituirani pirazolo-(1,5-a)pirimidinski derivati | |
| PH12020551465A1 (en) | Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds | |
| IL267801A (en) | Process for the preparation of 3-disubstituted 5-amino-h6-thiazolo[5,4-d]pyrimidine-7,2-dione compounds | |
| CO2017010621A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades |